Business Wire

MERCANS

14.9.2022 19:07:33 CEST | Business Wire | Press release

Share
NelsonHall Names Mercans as a Global Payroll Technology Leader in NEAT Assessment for Payroll Services 2022

Mercans, the global payroll technology leader, has been named a Leader in NelsonHall’s annual NEAT assessment of the leading payroll companies across the globe. NelsonHall has ranked Mercans highly as a Multi-Country Payroll firm for its ability to meet the future needs of global payroll clients as well as for its ability to deliver immediate benefits to its clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005728/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Payroll Services NEAT 2022 Mercans MCP (Graph: AETOSWire)

“We are delighted that NelsonHall has recognized Mercans as a leader in the global payroll industry. There is no other solution available in the market that enables clients to generate payrolls across 160 countries on a single platform,” said Andre Voolaid, Mercans’ CTO.

Mercans’ Chief Operating Officer, K A Viswanathan added, “Mercans continues to disrupt the payroll industry by doing what no other provider has been able to accomplish. We deliver global payroll services without using sub-contractors or third-party software. Our end-to-end payroll software integrates seamlessly with all major HCM solutions or can be used as a stand-alone digital payroll platform. Companies of any size can finally achieve full automation of their international payroll operations while reducing their operating costs.

Liz Rennie, NelsonHall’s HR Technology and Services Research Director said, “Mercans is a Leader in the multi-country payroll services market, offering 160-country payroll services through a single platform, HR Blizz, one of the largest payroll engines available in the market. The single payroll engine approach delivers a hassle-free multi-country payroll process, enabling clients to benefit from cost reductions. Mercans’ leadership position is also a result of its flexibility in offering both SaaS and managed payroll services, as well as bringing strong capability with an experienced and efficient team that is greatly valued by its clients.”

Mercans’ proprietary payroll platform HR Blizz™ is fully integrated with many human capital management platforms, including Workday, UKG, Dayforce, SuccessFactors, Oracle, and Darwinbox, as well as with the leading ERP solutions and local statutory authorities.

NelsonHall also ranked Mercans as a Leader in its Digital payroll and Comprehensive Payroll categories. This is a testament to Mercans’ industry-leading ability to deliver fully automated and digitalized global payroll solution, while delivering outstanding customer services and compliance experience across 160 countries.

“Our in-country service delivery and compliance teams, coupled with the best technology in the industry, have made Mercans a game changer in the payroll industry. We have changed the global payroll and we are excited that this has been noticed by NelsonHall,” concluded Tatyana Domovits, the CEO of Mercans Group.

About Mercans

Mercans is a global leader in payroll technology and employer of record services. Mercans’ revolutionary global payroll platform, HR Blizz™ enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform. Visit www.mercans.com

LinkedIn

About NelsonHall

NelsonHall is the leading global analyst firm dedicated to helping organizations understand the ‘art of the possible’ in digital operations transformation. With analysts in the U.S., U.K., Continental Europe, and India, NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors (including NEAT assessments) that helps them make fast and highly informed sourcing decisions. And for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall’s research is based on rigorous, primary research, and is widely respected for the quality, depth, and insight of its analysis.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005728/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye